Summary
Eli Lilly and Company's first quarter 2007 report shows a significant increase in net sales, up 14% to $4.23 billion, driven by strong performance from Cymbalta, Zyprexa, and the recently acquired Cialis (following the ICOS Corporation acquisition). However, net income and earnings per share saw a substantial decrease of 39% to $508.7 million and $0.47, respectively. This decline is primarily attributed to significant one-time charges, including $303.5 million for acquired in-process research and development from the ICOS acquisition and $123.0 million for asset impairments and restructuring. The company also provided updated financial guidance for 2007, expecting sales growth in the low double digits and earnings per share between $2.63 and $2.73.
Key Highlights
- 1Net sales increased by 14% year-over-year to $4.23 billion, fueled by key products like Cymbalta, Zyprexa, and the newly acquired Cialis.
- 2Net income decreased by 39% to $508.7 million, largely impacted by significant charges related to the ICOS acquisition and restructuring activities.
- 3The acquisition of ICOS Corporation for approximately $2.3 billion was completed in January 2007, bringing full ownership of Cialis and adding $628.4 million in goodwill.
- 4Research and development expenses increased by 13% to $834.2 million, reflecting continued investment in pipeline development and costs associated with regulatory setbacks like Arxxant.
- 5Marketing and administrative expenses rose by 17% to $1.34 billion, primarily due to the ICOS acquisition, increased marketing efforts for key products, and higher litigation costs.
- 6The company settled a substantial majority of US Zyprexa product liability claims, agreeing to settle approximately 28,500 claims, with ongoing litigation for the remaining ~1,300 plaintiffs.
- 7Eli Lilly is facing ongoing government investigations related to marketing and promotional practices for Zyprexa and other products, with potential for significant financial impact.
Frequently Asked Questions
The substantial decrease in net income was primarily due to significant one-time charges incurred during the quarter. These included $303.5 million in acquired in-process research and development (IPR&D) related to the ICOS acquisition and $123.0 million for asset impairments and restructuring. These charges significantly impacted profitability, even though revenue growth remained strong.
The acquisition of ICOS Corporation is expected to enhance future performance by bringing the full value of Cialis under Lilly's control, allowing for operational efficiencies in its development, marketing, and sales. While it incurred significant upfront costs, including IPR&D charges and goodwill, it is anticipated to contribute positively to sales and profitability in the long term. The financial results for the quarter already include Cialis sales post-acquisition.
Eli Lilly is confident in maintaining its US patent protection for Zyprexa until 2011, as a district court ruling upholding the patent was affirmed by the Court of Appeals. However, the company has settled a substantial majority of the US Zyprexa product liability claims, with approximately 1,300 claims remaining. The company is also actively defending against ongoing government investigations related to Zyprexa's marketing and promotional practices, which could lead to significant financial penalties.
Following the ICOS acquisition, Eli Lilly's cash, cash equivalents, and short-term investments decreased due to the acquisition cost and dividend payments. Total debt increased significantly by $1.64 billion to $5.36 billion, primarily due to $2.5 billion in new debt issued to finance the ICOS acquisition and related refinancing. The company expects strong cash flow from operations to be sufficient for its operating needs, including debt service, dividends, and capital expenditures.